Long/short equity, biotech, healthcare, small-cap

Salix Pharmaceuticals: Why You Shouldn't Be Dumping This Stock

Salix Pharmaceuticals (NASDAQ:SLXP) is a specialist pharmacy company that develops, acquires and commercializes prescription drugs, and medical devices used in the treatment of various forms of GI diseases. Gastrointestinal, or GI, disease is one of the most widespread diseases in the U.S., and it results in substantial morbidity, mortality, and healthcare costs. The most prevalent form of these diseases are non-food-borne gastroenteritis, GI infections, food borne illness, gastro esophageal reflux disease, gallbladder disease, irritable bowel syndrome, and opioid-induced constipation.

Salix offers tablets such as Xifaxan, Moviprep, Osmoprep, Apriso, Giazo, Colazal, Fulyzaq, Solesta, Deflux, etc.

Currently Salix is gaining traction with its drugs -- Relistor and Xifaxan, which are awaiting FDA approval. However due to the uncertainty surrounding the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details